ClinicalTrials.gg
Not yet recruitingNCT06431971LIBRAUpdated Oct 30, 2026

Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease

A Phase 2 interventional study of Talineuren and Placebo in Parkinson Disease, sponsored by InnoMedica Schweiz AG. Not yet recruiting at 6 sites in Switzerland. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by InnoMedica Schweiz AG · Phase 2, Interventional, and Treatment

How we know

Updated Oct 30, 2026Start date movedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.

Planned enrollment
25th of 67
40 · median 30
Started
2027
the only one that year
Phase 2
6 of 85
1 open now
Primary completion
2027-12
later than 23 of 33 live
Registered
65th of 85
by date

Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 25th largest by planned enrollment of the 67 interventional ones that give a count, is the only one that started in 2027, is one of 6 in phase 2, reaches primary completion later than 23 of the 33 other live ones, and was the 65th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Parkinson Disease with a site in Switzerland, or all of them as a file.
02

Study summary

This study is double-blinded placebo controlled followed by an open-label extension placebo-to-active switch to estimate the efficacy of Talineuren. The investigational Medicinal Product (IMP) is administrated 48 times intravenously as an add-on therapy to the standard of care Parkinson medication.

Talineuren is a liposomal formulation containing GM1 (monosialotetrahexosylganglioside) as the pharmacological active substance.

The results of this pilot study are essential for the sample size calculation of a subsequent larger phase II/III trial.

Read the detailed description

The ganglioside lipid GM1 (monosialotetrahexosylganglioside) has attracted attention in scientific literature as a promising neuroprotective agent. Research suggests that GM1 ganglioside holds promise not only in the treatment of neurodegenerative disorders like Parkinson disease (PD) and Alzheimer's disease but also in promoting nerve regeneration post-injury. Furthermore, investigations into its potential to improve cognitive function and memory underscore its versatility as a therapeutic agent. Numerous clinical studies have demonstrated its therapeutic potential in treating (PD) patients.

Talineuren (TLN) represents a novel approach to harnessing the therapeutic benefits of GM1. TLN is a liposomal formulation, comprising GM1 as its pharmacologically active ingredient, which is expected to cross the blood-brain barrier more efficiently as free GM1 and therefore is able to deliver more GM1 to the brain. This innovative composition is designed to optimize the neuroprotective effects of GM1.

Study Description:

This study is designed as a double-blinded, placebo-controlled trial with open-label placebo-to-active switch to evaluate the efficacy of TLN in PD management. The investigational Medicinal Product (IMP), TLN, is weekly intravenously administered a maximum of 48 times as an add-on therapy alongside patients' current standard-of-care PD medication. Talineuren, encapsulating GM1 within liposomes, is anticipated to facilitate enhanced delivery and bioavailability of the neuroprotective agent, GM1.

Objectives:

The primary objective is to estimate differences between PD patients treated with Talineuren and those receiving placebo regarding their average MDS-UPDRS part III score in the defined "off" medication state (part of the Levodopa challenge test (LCT); motor symptoms evaluated by a physician) over a study period of 6 months.

Secondary objectives are to obtain the change from baseline and variance of TLN and placebo and compare these between the groups for :

  • MDS-UPDRS total score (part I + part II + part III "off" + part IV)
  • MDS-UPDRS part I (non-motor symptoms in daily life)
  • MDS-UPDRS part II (motor symptoms in daily life)
  • MDS-UPDRS part III "on medication"
  • MDS-UPDRS total part IV (motor complications)
  • Proportion of patients meeting or exceeding the minimum clinically important difference (MCID) in motor and non-motor symptoms (MDS-UPDRS) and quality of life (PDQ-39) over time
  • Quality of life (PDQ-39, EQ-5D-5L)
  • Mental condition (MoCA)
  • Parkinson medication (LEDD)
  • Digital biomarker: voice analysis

Research objectives (biomarkers):

-Assessment of literature-described biomarkers (prognostic, predictive, monitoring and/or response biomarkers) pre- and post-TLN or placebo intervention.

Through evaluation and statistical analysis, this study seeks to elucidate the therapeutic potential of TLN in addressing the multifaceted challenges of Parkinson's disease. By providing insights into treatment efficacy, medication usage, symptom management, and quality of life improvements, our findings aim to inform future advancements in PD management and enhance patient care.

The results of this pilot study are essential for the sample size calculation of a subsequent larger phase II/III trial.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature.
  • Male and female subjects, aged 30 to 85 years.
  • Confirmed PD according to British brain bank criteria.
  • Hoehn and Yahr Stage 0 - 2.5 on medication and on stimulation (DBS, if applicable).
  • Stable dopaminergic PD treatment (including DBS) for a month at least.
  • Absence of dementia confirmed by cognitive testing ( ≥24).

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with Talineuren (i.e. participants from NEON trial are not allowed)
  • to the drug classes of standard of care medication and the medicinal product, (e.g., known or allergy) and contraindications as listed in the product information of marketed products.
  • Known / suspected diagnosis of hereditary fructose intolerance.
  • Prior Campylobacter-jejuni-gastroenteritis or prior occurrence of Guillain-Barré-Syndrome.
  • Women who are pregnant or breast feeding, or planning to become pregnant during the course of the trial or in the 12 weeks following the trial.
  • Lack of safe , defined as: Female participants of , not willing to use double method of contraception (hormonal and mechanical) for the entire study duration. Note: Female participants who are surgically sterilised / hysterectomised or for longer than 2 years are not considered as being of child bearing potential.

Male participants, not using and not willing to use a medically reliable method of contraception for the entire study duration, such as condoms or who are not using any other method considered sufficiently reliable by the investigator in individual cases.

  • Inability to follow the procedures of the trial, e.g., due to language problems, psychological disorders etc. of the participant.
  • Participation in another trial with an investigational drug within the 30 days preceding and during the present trial.
  • Enrolment of the investigator, his/her family members, employees and other dependent persons.
  • Subject has an atypical parkinsonian syndrome or secondary parkinsonism.
  • Patients in adjustment of deep brain stimulation (DBS) parameters
  • Patients with concomitant diseases (e.g., renal failure, hepatic dysfunction, cardiovascular disease, infections, etc.) that are not under stable control.
  • Known or suspected non-compliance, drug or alcohol abuse.
  • Patients with comorbidity that may interfere with the course of the trial.
  • Patients with an established diagnosis of clinically relevant bone marrow dysfunction affecting leukopoiesis or with active hematological or with a clinically relevant immunodeficiency.
  • Concomitant use of myelotoxic (e.g. cytostatic agents) and/or other drugs with clinically relevant effects (e.g. calcineurin inhibitors) and/or drugs associated with a clinically relevant impairment of granulopoiesis.
  • Patients who are not considered to be eligible to participate in clinical trial by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Talineuren

    Participants receive standard of care PD treatment + Talineuren i.v. weekly starting with a dose escalation of 12 mg, 60 mg and 360 mg Talineuren followed by 720 mg Talineuren for 21 weeks (24 infusions, 24 weeks in total) during the double-blind phase. Participants may continue in an open-label extension phase and receive 720 mg of Talineuren i.v. weekly for additional 24 infusions (24 weeks).

    Drug: Talineuren

  • Placebo comparator
    Placebo

    Participants receive standard of care PD treatment + placebo (0.9% NaCl) i.v. weekly for 24 infusions (24 weeks) in the double-blind phase. Participants may continue in an open-label extension phase and will receive Talineuren i.v. weekly starting with a dose escalation of 12 mg, 60 mg and 360 mg Talineuren followed by 720 mg Talineuren for 21 infusions (24 infusions, 24 weeks in total).

    Drug: Placebo

Interventions

  • DrugTalineuren

    Talineuren infusion weekly

    Also known as: TLN, Liposomal GM1

  • DrugPlacebo

    Placebo infusion weekly

    Also known as: 0.9% NaCl

06

What researchers measure

Primary outcomes

  1. Movement Disorder Society Unified Parkinson's Disease Rating Scale score

    The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) will be used by the patient and physician to evaluate various symptoms of Parkinson disease including non-motor and motor experiences of daily living and motor complications. The MDS-UPDRS Scale consists of 4 parts: * Part 1 (Nonmotor aspects of experiences of daily living) with 13 items. * Part 2 (Motor aspects of experiences of daily living) with 13 items. * Part 3 (Motor examination) with 18 items. * Part 4 (Motor complications) with 6 items. Each item is rated with 0=normal, 1=slight, 2=mild, 3=moderate, 4=severe. The lower the score, the fewer / less severe the symptoms.

    Time frame: Baseline, week 25 (primary endpoint)

Secondary outcomes

  1. Parkinson disease Quality of Life Questionnaire score

    Parkinson disease Quality of Life Questionnaire (PDQ-39) will be completed by the patient. The proportion of patients reaching or exceeding the minimal clinical important difference (MCID) will be assessed. This questionnaire consists of 39 items in 8 dimensions with 0 = perfect health, 100 = worse health.

    Time frame: Baseline, week 25, week 49

  2. Montreal Cognitive Assessment score

    Patient's mental condition is assessed using the Montreal Cognitive Assessment (MoCA) by the physician together with the patient where the patient can reach a score of 0-30. A final total score of 26 and above is considered normal.

    Time frame: Baseline, week 25, week 49

  3. Change in Levodopa equivalent daily dose

    Levodopa equivalent daily dose (LEDD) in \[mg\] will documented at each study visit.

    Time frame: Through study completion, an average of 56 weeks

  4. Movement Disorder Society Unified Parkinson's Disease Rating Scale score

    The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) will be used by the patient and physician to evaluate various symptoms of Parkinson disease including non-motor and motor experiences of daily living and motor complications. The MDS-UPDRS Scale consists of 4 parts: * Part 1 (Nonmotor aspects of experiences of daily living) with 13 items. * Part 2 (Motor aspects of experiences of daily living) with 13 items. * Part 3 (Motor examination) with 18 items. * Part 4 (Motor complications) with 6 items. Each item is rated with 0=normal, 1=slight, 2=mild, 3=moderate, 4=severe. The lower the score, the fewer / less severe the symptoms.

    Time frame: Baseline, week 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53

  5. EQ-5D-5L

    The EQ-5D-5L is a standardized, preference-based instrument used to assess health-related quality of life in clinical studies. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on five levels of severity ranging from no problems to extreme problems. This structure allows for a detailed description of a participant's health state and improves sensitivity compared to earlier versions. Health states are converted into a single utility index using country-specific value sets, enabling use in economic evaluations such as cost-utility analyses. In addition, the instrument includes a visual analogue scale, where participants rate their overall health on a scale from 0 to 100.

    Time frame: Baseline, week 25, week 49

  6. Change from Baseline in Voice-Based Disease Severity Prediction Score

    Speech samples will be recorded using the Virtuosis AI voice assessment platform. At each assessment, participants will provide a speech recording of at least 30 seconds in response to a standardized question. Automated algorithms will quantify speech features related to voice quality, prosody, articulation, fluency, and speech rate. Based on raw acoustic measures (e.g., dB and Hz), corresponding z-scores, and their position relative to Parkinson's disease-specific thresholds, an overall voice score will be generated. Changes in the overall voice score over time will be assessed.

    Time frame: Baseline to week 53 (measured twice weekly)

Other outcomes

  1. Number of IMP-related adverse events

    Incidence and severity of treatment-emergent AEs (TEAEs) from the start of the treatment until the safety visit (week 56) using CTCAE criteria (V6.0).

    Time frame: From the date of the first administration (week 1) until week 53

  2. Proportion of feasibility parameters

    Collecting of information for a subsequent larger phase II trial. The following information will be assessed: * Acceptance proportion: the proportion of patients willing to participate in this trial * Drop-out proportion \& reason: the proportion of enrolled subjects who pre-maturely discontinue the trial. The reason for the discontinuation shall be recorded, if possible, so to be able to identify any potential issues in the design and procedures of the trial that can be improved for the subsequent trial. * Failure proportion of IMP-administration: Proportion of visits that need to be rescheduled because no vein for IMP-administration is found.

    Time frame: Screening to week 53

  3. Mean values of Biomarkers

    -To detect and assess the presence of blood-derived biomarkers selected from literature at baseline and end of intervention, and to compare the obtained values in between treatment groups

    Time frame: Baseline, week 25, week 49

  4. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Treatment-emergent adverse events (TEAEs) will be assessed from the start of treatment until the primary endpoint visit at Week 25. TEAEs will be summarized by incidence and severity.

    Time frame: From the date of the first administration (week 1) to primary endpoint visit (25 weeks)

  5. Absolute Neutrophil Count (ANC)

    Absolute neutrophil count (ANC) will be measured at predefined time points before, during, and after infusions to assess changes in neutrophil levels associated with treatment.

    Time frame: Week 1, 2, 3, 4, 5, 9, 13, 17, 21

07

Study locations

6 sites
  • Kantonsspital Aarau (KSA), Neurologische Klinik
    Aarau, Canton of Aargau 5001, Switzerland
    • Tobias Piroth, Dr. med. · Contact
  • Hôpitaux Universitaires de Genève (HUG), Département des Neurosciences cliniques NEUCLI, Service de Neurologie
    Geneva, Canton of Geneva 1205, Switzerland
    • Vanessa Fleury, Dr. · Contact
  • Health Ostschweiz/ Kantonsspital St. Gallen (KSSG), Klinik für Neurologie
    Sankt Gallen, Canton of St. Gallen 9007, Switzerland
    • Florian Brugger, PD Dr. med. · Contact
  • Centre hospitalier universitaire Vaudois (CHUV), Clinical Neurosciences Department
    Lausanne, Canton of Vaud 1011, Switzerland
    • Julien Bally, Dr. · Contact
  • Bellevue Medical Group AG (BMG), Neurozentrum Seefeld
    Zurich, Canton of Zurich 8008, Switzerland
    • Kerstin Schweyer, Dr. med. · Contact
  • Neurologisches Institut Konolfingen
    Konolfingen, 3510, Switzerland
    • Michael Schüpbach, Dr. med. · Contactnik@hin.ch · +41 31 790 01 30
    • Michael Schüpbach, Dr. med · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's planned 11 months is below that.

Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Aug 2024 → Jan 2027, primary completion Nov 2025 → Dec 2027 and completion Dec 2025 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
May 29, 2024
StartEst.
Jan 2027was Aug 2024
Primary completionEst.
Dec 2027was Nov 2025
CompletionEst.
Jul 2028was Dec 2025
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added
Show 5 added (5 Switzerland)
  • Kantonsspital Aarau (KSA), Neurologische Klinik · Aarau, Switzerland
  • Hôpitaux Universitaires de Genève (HUG), Département des Neurosciences cliniques NEUCLI, Service de Neurologie · Geneva, Switzerland
  • Health Ostschweiz/ Kantonsspital St. Gallen (KSSG), Klinik für Neurologie · Sankt Gallen, Switzerland
  • Centre hospitalier universitaire Vaudois (CHUV), Clinical Neurosciences Department · Lausanne, Switzerland
  • Bellevue Medical Group AG (BMG), Neurozentrum Seefeld · Zurich, Switzerland
Oct 30, 2026
Start date
Aug 2024→Jan 2027
Oct 30, 2026
Primary completion
Nov 2025→Dec 2027
Oct 30, 2026
Study completion
Dec 2025→Jul 2028
Oct 30, 2026
Eligibility
1 inclusion criterion edited; 3 exclusion criteria edited, 4 added, 3 removed
What changed in the criteria
Inclusion criteria
  • EditedHoehn and Yahr Stage 0 - 2.5 on medication and on stimulation (DBS, if applicable).
Exclusion criteria
  • EditedContraindications to the classdrug classes of drugs under studystandard of care medication and the investigational medicinal product, (e.g., known hypersensitivity or allergy to class) and contraindications as listed in the product information of drugs or the investigationalmarketed products.
  • AddedKnown / suspected diagnosis of hereditary fructose intolerance.
  • AddedPrior Campylobacter-jejuni-gastroenteritis or prior occurrence of Guillain-Barré-Syndrome.
  • RemovedLack of safe contraception, defined as:
  • RemovedFemale participants of childbearing potential, not willing to use double method of contraception (hormonal and mechanical) for the entire study duration.
  • EditedLack of safe contraception, defined as: Female participants of childbearing potential, not willing to use double method of contraception (hormonal and mechanical) for the entire study duration. Note: Female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
  • RemovedPatients with known impaired granulopoiesis
  • EditedOtherPatients with clinically significant concomitant diseases states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, infections, etc.) that is are not under stable control.
  • AddedPatients with an established diagnosis of clinically relevant bone marrow dysfunction affecting leukopoiesis or with active hematological malignancies or with a clinically relevant immunodeficiency.
  • AddedConcomitant use of myelotoxic (e.g. cytostatic agents) and/or other drugs with clinically relevant immunosuppressive effects (e.g. calcineurin inhibitors) and/or drugs associated with a clinically relevant impairment of granulopoiesis.
Oct 30, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameMovement Disorder Society Unified Parkinson's Disease Rating Scale scoreBaseline, week 7, 11, 15, 19 and 22 → Baseline, week 25 (primary endpoint)
Oct 30, 2026
Secondary outcomes
6 time frame changed, 5 added, 1 description edited
What changed in the outcomes
  • AddedMovement Disorder Society Unified Parkinson's Disease Rating Scale scoreTime frame: Baseline, week 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53
  • AddedEQ-5D-5LTime frame: Baseline, week 25, week 49
  • AddedChange from Baseline in Voice-Based Disease Severity Prediction ScoreTime frame: Baseline to week 53 (measured twice weekly)
  • Time frameParkinson disease Quality of Life Questionnaire scoreBaseline, week 19 → Baseline, week 25, week 49
  • Time frameMontreal Cognitive Assessment scorebaseline, week 19 → Baseline, week 25, week 49
  • Time frameChange in Levodopa equivalent daily doseThrough study completion, an average of 22 weeks → Through study completion, an average of 56 weeks
  • Addedother outcomeNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From the date of the first administration (week 1) to primary endpoint visit (25 weeks)
  • Addedother outcomeAbsolute Neutrophil Count (ANC)Time frame: Week 1, 2, 3, 4, 5, 9, 13, 17, 21
  • Time frameother outcomeNumber of IMP-related adverse eventsFrom the date of the first administration until week 22 → From the date of the first administration (week 1) until week 53
  • Time frameother outcomeProportion of feasibility parametersUp to week 22 → Screening to week 53
  • Time frameother outcomeMean values of BiomarkersBaseline, week 19 → Baseline, week 25, week 49
  • Descriptionother outcomeNumber of IMP-related adverse events: how it is measured was reworded
Oct 30, 2026
Contact
Study contact now listed: added i•••@innomedica.com · •••0427. See the current contact
Oct 30, 2026
Title
Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    5 sites added
    Show 5 added (5 Switzerland)
    • Kantonsspital Aarau (KSA), Neurologische Klinik · Aarau, Switzerland
    • Hôpitaux Universitaires de Genève (HUG), Département des Neurosciences cliniques NEUCLI, Service de Neurologie · Geneva, Switzerland
    • Health Ostschweiz/ Kantonsspital St. Gallen (KSSG), Klinik für Neurologie · Sankt Gallen, Switzerland
    • Centre hospitalier universitaire Vaudois (CHUV), Clinical Neurosciences Department · Lausanne, Switzerland
    • Bellevue Medical Group AG (BMG), Neurozentrum Seefeld · Zurich, Switzerland
    Start date Aug 2024→Jan 2027
    Primary completion Nov 2025→Dec 2027
    Study completion Dec 2025→Jul 2028
    Eligibility 1 inclusion criterion edited; 3 exclusion criteria edited, 4 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • EditedHoehn and Yahr Stage 0 - 2.5 on medication and on stimulation (DBS, if applicable).
    Exclusion criteria
    • EditedContraindications to the classdrug classes of drugs under studystandard of care medication and the investigational medicinal product, (e.g., known hypersensitivity or allergy to class) and contraindications as listed in the product information of drugs or the investigationalmarketed products.
    • AddedKnown / suspected diagnosis of hereditary fructose intolerance.
    • AddedPrior Campylobacter-jejuni-gastroenteritis or prior occurrence of Guillain-Barré-Syndrome.
    • RemovedLack of safe contraception, defined as:
    • RemovedFemale participants of childbearing potential, not willing to use double method of contraception (hormonal and mechanical) for the entire study duration.
    • EditedLack of safe contraception, defined as: Female participants of childbearing potential, not willing to use double method of contraception (hormonal and mechanical) for the entire study duration. Note: Female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
    • RemovedPatients with known impaired granulopoiesis
    • EditedOtherPatients with clinically significant concomitant diseases states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, infections, etc.) that is are not under stable control.
    • AddedPatients with an established diagnosis of clinically relevant bone marrow dysfunction affecting leukopoiesis or with active hematological malignancies or with a clinically relevant immunodeficiency.
    • AddedConcomitant use of myelotoxic (e.g. cytostatic agents) and/or other drugs with clinically relevant immunosuppressive effects (e.g. calcineurin inhibitors) and/or drugs associated with a clinically relevant impairment of granulopoiesis.
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameMovement Disorder Society Unified Parkinson's Disease Rating Scale scoreBaseline, week 7, 11, 15, 19 and 22 → Baseline, week 25 (primary endpoint)
    Secondary outcomes 6 time frame changed, 5 added, 1 description edited
    What changed in the outcomes
    • AddedMovement Disorder Society Unified Parkinson's Disease Rating Scale scoreTime frame: Baseline, week 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53
    • AddedEQ-5D-5LTime frame: Baseline, week 25, week 49
    • AddedChange from Baseline in Voice-Based Disease Severity Prediction ScoreTime frame: Baseline to week 53 (measured twice weekly)
    • Time frameParkinson disease Quality of Life Questionnaire scoreBaseline, week 19 → Baseline, week 25, week 49
    • Time frameMontreal Cognitive Assessment scorebaseline, week 19 → Baseline, week 25, week 49
    • Time frameChange in Levodopa equivalent daily doseThrough study completion, an average of 22 weeks → Through study completion, an average of 56 weeks
    • Addedother outcomeNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From the date of the first administration (week 1) to primary endpoint visit (25 weeks)
    • Addedother outcomeAbsolute Neutrophil Count (ANC)Time frame: Week 1, 2, 3, 4, 5, 9, 13, 17, 21
    • Time frameother outcomeNumber of IMP-related adverse eventsFrom the date of the first administration until week 22 → From the date of the first administration (week 1) until week 53
    • Time frameother outcomeProportion of feasibility parametersUp to week 22 → Screening to week 53
    • Time frameother outcomeMean values of BiomarkersBaseline, week 19 → Baseline, week 25, week 49
    • Descriptionother outcomeNumber of IMP-related adverse events: how it is measured was reworded
    Contact Study contact now listed: added i•••@innomedica.com · •••0427. See the current contact
    Title Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease
    + 4 other changes: index terms, verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06431971
Lead sponsor
InnoMedica Schweiz AG
Responsible party
Sponsor
First posted
May 29, 2024
Start date
Jan 2027 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Florian Peters, PhD
Contact
info@innomedica.com
+41 31 311 04 27

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion